Disease · MONDO_0004907

alopecia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. alopecia. Diseases, record MONDO_0004907. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004907

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: alopecia; Open Targets
Open Targets ID: MONDO_0004907; Open Targets
Other names: hair loss, loss Of hair; Open Targets
Disease Ontology: DOID:987; Disease Ontology
MeSH: D000505; MeSH
NCI Thesaurus: C50575; NCI Thesaurus
Orphanet: ORPHA:79364; Orphanet
Highest stage of its drugs: Approval, for 2 of its 15 drugs, from PMDA and TTD; Open Targets

Drugs15

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BIMATOPROST	CHEMBL1200963	Small molecule	Approval	TTD	2	1	1	Drugs and targets
DUTASTERIDE	CHEMBL1200969	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
DEURUXOLITINIB	CHEMBL4594381	Small molecule	Phase 3	ClinicalTrials.gov	2	1	1	Drugs and targets
RITLECITINIB	CHEMBL4085457	Small molecule	Phase 2/3	ClinicalTrials.gov and TTD	2	1	1	Drugs and targets
DALOSIRVAT	CHEMBL4650339	Small molecule	Phase 2/3	TTD	1	0	0	Drugs and targets
MINOXIDIL	CHEMBL802	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
DIMETHYLCURCUMIN	CHEMBL128748	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
DIPHENCYPRONE	CHEMBL1373467	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
FAZIRSIRAN	CHEMBL5095435	Oligonucleotide	Phase 2	TTD	1	0	0	Drugs and targets
IFIDANCITINIB	CHEMBL4594441	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets

1 to 10 of 15

See all 15 drugs

Targets21

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
JAK3	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Phase 2/3	https://conductscience.org/library/genes/3718	Drugs and targets
ABCC9	Sulfonylurea receptor 2, Kir6.2	1	Sulfonylurea receptor 2, Kir6.2 opener	Phase 2	https://conductscience.org/library/genes/10060	Drugs and targets
AR	Androgen receptor	1	Androgen Receptor degrader	Phase 2	https://conductscience.org/library/genes/367	Drugs and targets
BMX	TEC family kinase	1	TEC family kinase inhibitor	Phase 2/3	https://conductscience.org/library/genes/660	Drugs and targets
BTK	TEC family kinase	1	TEC family kinase inhibitor	Phase 2/3	https://conductscience.org/library/genes/695	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 1	https://conductscience.org/library/genes/2280	Drugs and targets
IL17A	Interleukin-17A	1	Interleukin 17A inhibitor	Phase 2	https://conductscience.org/library/genes/3605	Drugs and targets
ITK	TEC family kinase	1	TEC family kinase inhibitor	Phase 2/3	https://conductscience.org/library/genes/3702	Drugs and targets
JAK1	Janus Kinase (JAK)	1	Janus Kinase (JAK) inhibitor	Unknown	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	1	Janus Kinase (JAK) inhibitor	Unknown	https://conductscience.org/library/genes/3717	Drugs and targets

1 to 10 of 21

See all 21 targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03732807	PF-06651600 for the Treatment of Alopecia Areata	Phase 2/3	718	2022-02-24	Alopecia Areata	RITLECITINIB	Its record names the disease	ClinicalTrials.gov
NCT05041803	European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata	Phase 3	407	2025-11-21	Alopecia Areata	DEURUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT01189279	Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia	Phase 1	42	2013-08-30	Alopecia, Alopecia, Androgenetic, Baldness	BIMATOPROST	Its record names the disease	ClinicalTrials.gov
NCT07101471	Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation		296		Alopecia Totalis/Universalis, Alopecia Areata(AA)	TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT05417308	Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer	Early phase 1	50		Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Endocrine Therapy-Induced Alopecia, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8	MINOXIDIL	Its record names the disease	ClinicalTrials.gov
NCT07594678	Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients	Phase 2	50		Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Alopecia	MINOXIDIL	Its record names the disease	ClinicalTrials.gov
NCT00177099	Effects of Ligands on Human Hair Follicles Grafted Onto SCID Mice	Phase 1	35		Alopecia	TACROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT03491267	Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis	Early phase 1	24		Central Centrifugal Cicatricial Alopecia (CCCA)	TRETINOIN	Its record names the disease	ClinicalTrials.gov
NCT03831334	Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia	Early phase 1	14		Permanent Chemotherapy-induced Alopecia	MINOXIDIL	Its record names the disease	ClinicalTrials.gov
NCT05778825	A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors	Phase 2	10		Survivors of Childhood Cancer, Alopecia	MINOXIDIL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
CTP-543 8 mg BID vs CTP-543 12 mg BID: deaths from any cause	0 of 367	0 of 273	640	NCT05041803	Trial comparisons
CTP-543 8 mg BID vs CTP-543 12 mg BID: Number of Participants With Adverse Events as a Measure of Safety	308 of 367	224 of 273	640	NCT05041803	Trial comparisons
CTP-543 8 mg BID vs CTP-543 12 mg BID: serious adverse events	16 of 367	5 of 273	640	NCT05041803	Trial comparisons

Papers from its trials17

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38823686	RESULT	1	PubMed
29273099	RESULT	1	PubMed
27816293	RESULT	1	PubMed
42823604	DERIVED	1	PubMed
42481842	DERIVED	1	PubMed
41917311	DERIVED	1	PubMed
41005700	DERIVED	1	PubMed
40261547	DERIVED	1	PubMed
39962358	DERIVED	1	PubMed
39441519	DERIVED	1	PubMed

1 to 10 of 17

See all 17 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004907

GET https://conductscience.org/api/diseases/v1/MONDO_0004907/targets?page=2

API reference For AI assistants